Shiyu Liu

Mr. Shiyu Liu


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2023 in Discover Oncology
Verified
Journal Article
Open access
PDF file
YHYi Han
Yi Han
GCGang Chen
Gang Chen
SLShiyu Liu
Shiyu Liu
GZGuangqing Zhou
Guangqing Zhou
XXXinxin Xu
Xinxin Xu
GCGuangxia Chen
Guangxia Chen
Background: Esophageal cancer is one of the most common malignant tumors in the world, which is characterized by poor prognosis, aggressiveness, and poor survival. Mucin 13 (MUC13) is a member of the membrane-bound mucin and located on chromosome 3q21.2 and consists of α and β subunits. It has been found that MUC13 is overexpressed in a variety of tumor cells and acts a vital role in the invasiveness and malignant progression of several types of tumors. However, the role and regulatory mechanism of MUC13 in the progression of esophageal cancer remain unclear. Methods: The expression level of MUC13 was detected in 15 esophageal cancer tissues and 15 pairs of adjacent nontumor tissues by immunohistochemistry (IHC). In addition, the expression of MUC13 mRNA level in human esophageal cancer cell lines (EC9706 and ECA109 and TE-1) was measured by qRT-PCR. In vitro, after silencing MUC13 with lentiviral interference technology, CCK8 assay, clone formation assay, and flow cytometry were applied to investigate the proliferation activity, clone formation ability and anti-apoptosis ability of EC9706 and ECA109 cells. The tumor xenograft growth assay was used to confirm the influence of MUC13 knockdown on the growth of esophageal tumors in vivo. The qRT-PCR assay and western blot experiments were taken to study the mechanism of MUC13 regulating the proproliferation and antiapoptotic of esophageal cancer. Results: The results showed that MUC13 was overexpressed in esophageal cancer tissues and cell lines (EC9706 and ECA109 and TE-1), especially in EC9706 and ECA109 cells, but low expressed in human esophageal epithelial cell line (HEEC). Next, silencing MUC13 inhibits proliferation, blocks cell cycle progression, and promotes cell apoptosis in vitro, and restrains the growth of esophageal cancer tissues in vivo. Finally, MUC13 affects the proproliferation and antiapoptotic by regulating the expression of GLANT14, MUC3A, MUC1, MUC12, and MUC4 that closely related to O-glycan process. Conclusions: This study proved that MUC13 is an important molecule that regulates the O-glycan process and then affects the progress of esophageal cancer. MUC13 may be a novel therapeutic target for patients with esophageal cancer.

3 March 2026 in Ecotoxicology and Environmental Safety
Verified
Journal Article
Open access
JTJiajia Tong
Jiajia Tong
SLShiyu Liu
Shiyu Liu
TDTingting Du
Tingting Du
WLWangting Liu
Wangting Liu
ZJZiyi Jin
Ziyi Jin
GCGuangxia Chen
Guangxia Chen
To investigate the role of Benzo[a]pyrene (BaP) in driving the Correa cascade during gastric cancer development, we employed an integrated strategy combining network toxicology, machine learning, and molecular dynamics (MD) simulations. We identified 301 co-expressed genes spanning the Correa sequence, from chronic inflammation to invasive carcinoma. A protein-protein interaction network was constructed using STRING, and CytoHubba analysis highlighted five hub genes: TNF, IL6, IFNG, IL1B, and STAT3. Using CHEMBL and SUPER-PRED, we predicted 846 potential BaP targets. Intersection with disease-related genes revealed 62 common targets. Among eight candidate hub genes, an integrated Stepglm[both] and Random Forest model identified STAT3, TP53, and MMP9 as core targets. Receiver operating characteristic analysis confirmed their strong diagnostic potential (AUC > 0.78), while SHAP analysis ranked STAT3 as the most influential factor (SHAP = 0.241). Notably, these genes exhibited synergistic expression patterns in tumors (STAT3-TP53: ρ = 0.175; STAT3-MMP9: ρ = 0.261; TP53-MMP9: ρ = 0.216; all P < 0.01) and showed a dose-dependent association with disease progression. Genomic profiling revealed frequent mutations and amplifications in STAT3, TP53, and MMP9, with TP53 exhibiting the highest mutation rate. Analysis using UALCAN demonstrated significant upregulation of their mRNA levels in tumor tissues compared to normal tissues (P < 0.05). Clinically, high STAT3 and TP53 expression correlated with poorer survival, whereas elevated MMP9 levels were associated with improved outcomes. Mechanistic studies, including molecular docking and dynamics simulations, confirmed stable BaP-target interactions (e.g., STAT3 binding energy = -8.285 kcal/mol) mediated by non-covalent interactions, which disrupt the bidirectional STAT3-TP53 regulatory axis (STAT3 → MDM2 ⊣ TP53; TP53 → PIAS3 ⊣ STAT3). In summary, this study identifies STAT3, TP53, and MMP9 as central mediators of BaP-induced progression along the Correa cascade via a synergistic regulatory network. These findings provide new insights into environmental gastric carcinogenesis and highlight potential therapeutic strategies, including dual STAT3/MDM2 inhibition or MMP9 blockade.

11 September 2023 in Discover Oncology
Verified
Journal Article
Open access
PDF file
YHYi Han
Yi Han
GCGang Chen
Gang Chen
SLShiyu Liu
Shiyu Liu
GZGuangqing Zhou
Guangqing Zhou
XXXinxin Xu
Xinxin Xu
GCGuangxia Chen
Guangxia Chen